As filed with the United States Securities
and Exchange Commission on March 12, 2009

Registration No. 333-________





UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWashington, D.C.
20549


| |                             | 
| | --------------------------- | 
| |                             | 
| | FORM S-8                    | 
| | REGISTRATION STATEMENT      | 
| | Under                       | 
| | THE SECURITIES ACT OF
 1933 | 
|
| |                             | 

|                                                       
|-------------------------------------------------------
|MAKO
 Surgical Corp.                                   
|(Exact
 name of registrant as specified in its charter)

|                                |  |                    
|------------------------------- |  | -------------------
|Delaware                        |  | 20-1901148         
|(State or Other Jurisdiction of |  | (I.R.S. Employer   
|Incorporation or Organization)  |  | Identification No.)

|                                                              |                                | 
|------------------------------------------------------------- | ------------------------------ | 
|                                                              | 2555 Davie Road                | 
|                                                              | Fort Lauderdale, Florida 33317 | 
|(Address, Including Zip Code, of Principal Executive Offices)
|                                                              |                                | 
|                                                              |                                | 
|                                                             
|MAKO Surgical Corp. 2004 Stock
 Incentive Plan               
|                                                              | (Full Title of the Plan)       | 
|                                                              |                                | 
|                                                              |                                | 

Maurice R. Ferré, M.D.
President and Chief Executive Officer
MAKO Surgical Corp.2555 Davie Road, Fort Lauderdale, Florida 33317
(954) 927-2044(Name, Address and Telephone Number,
Including Area Code, of Agent for Service)

COPY TO:
Jay O. Rothman, Esq.Foley & Lardner LLP
777 East Wisconsin Avenue
Milwaukee, Wisconsin 53202
(414) 271-2400

Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer or a smaller reporting company. See the
definition of large accelerated filer, accelerated filer and smaller
reporting company in Rule 12b-2 of the Exchange Act. (Check one):

|                                                                                                                        |                                            
|----------------------------------------------------------------------------------------------------------------------- | -------------------------------------------
|Large accelerated filer   o     Accelerated
 filer   o     Non-accelerated filer   x     Smaller reporting
 company   o
|                                                                                                                        | (Do not check if smaller reporting company)

|                                |  | 
|------------------------------- |  | 
|                                |  | 
|                               
|CALCULATION OF REGISTRATION FEE

|                                          |  |                             |         |                                               |  |                                               |  |                              |               |  |  |         | 
|----------------------------------------- |  | --------------------------- | ------- | --------------------------------------------- |  | --------------------------------------------- |  | ---------------------------- | ------------- |  |  | ------- | 
|                                         
|Title of Securities
 To Be Registered     |  | Amount
 To Be Registered(1) |         | Proposed Maximum
 Offering Price
 Per Unit(2) |  | ProposedMaximum
 Aggregate Offering
 Price(2) |  | Amount of 
 Registration Fee |              
|                                         
|Common Stock, par value
 $0.001 per share |  |                             | 741,075 |                                               |  | $6.83                                         |  |                              | $5,061,542.25 |  |  | $198.92 | 
|                                         

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|(1) | This Registration Statement
 covers, in addition to the number of shares of Common Stock stated above,
 options and other rights to purchase or acquire the shares of Common Stock
 covered by the prospectus of the above-named plans, and, pursuant to Rule 416
 under the Securities Act of 1933, as amended (the Securities Act), any
 additional shares of Common Stock which become issuable under the above-named
 plans by reason of any stock dividend, stock split, recapitalization or other
 similar transaction effected without the receipt of consideration which
 results in an increase in the number of outstanding shares of Common Stock.
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|(2) | Pursuant to Rule 457(h) and
 (c) promulgated under the Securities Act, the maximum offering price, per
 share and in the aggregate, and the registration fee were calculated based
 upon the average of the high and low prices of the Common Stock on March 9,
 2009, as reported on the NASDAQ Global Market.                                                                                                                                                                                                                                                                                                                                                





---

| |                      | 
| | -------------------- | 
| | 741,075
 Shares      | 
| |                      | 
| |                      | 
| |                      | 
| |                      | 
| |                      | 
| | MAKO
 Surgical Corp. | 
| | Common Stock         | 
| |                      | 

This
prospectus relates to the registration of up to 741,075 shares of our common
stock that may be offered by the selling stockholder identified in this
prospectus or a prospectus supplement for his own account. The shares were
awarded to the selling stockholder under our 2004 Stock Incentive Plan. The
selling stockholder may offer and sell the shares covered by this prospectus
from time to time at prevailing market prices and privately negotiated prices.
The selling stockholder may offer the shares from time to time in one or more
transactions by any method permitted pursuant to applicable law. See Plan of
Distribution. The price at which any of the shares may be sold, and the
commissions, if any, paid in connection with any such sale, are unknown and may
vary from transaction to transaction.

We
have agreed to bear all expenses (other than direct expenses incurred by the
selling stockholder, such as selling commissions, brokerage fees and expenses
and transfer taxes) associated with registering the shares of common stock
covered by this prospectus under federal and state securities laws.

Our
common stock is listed on The NASDAQ Global Market under the symbol MAKO. On
March 9, 2009, the last sale price of our common stock as reported on The
NASDAQ Global Market was $6.91 per share.

We
will not receive any of the proceeds from the sale of the shares of common
stock covered by this prospectus.

None
of the shares of common stock covered by this prospectus have been registered
prior to the filing of our registration statement on Form S-8 of which this
prospectus is a part.

Investing in
our common stock involves risks. Before making any investment in the common
stock, you should carefully consider the risks that are described in the Risk
Factors section beginning on page 7 of this prospectus and in Part I, Item 1A,
Risk Factors, of our annual report on Form 10-K for the year ended December
31, 2008.

Neither the
Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if this prospectus is
truthful or complete. Any representation to the contrary is a criminal offense.

|                                               
|-----------------------------------------------
|                                               
|                                               
|The date of this prospectus is March 12,
 2009.

---

TABLE OF CONTENTS

|                                    |  |   
|----------------------------------- |  | --
|PROSPECTUS SUMMARY                  |  | 3 
|RISK FACTORS                        |  | 5 
|USE OF PROCEEDS                     |  | 9 
|SELLING STOCKHOLDER                 |  | 9 
|EXPERTS                             |  | 11
|WHERE YOU CAN FIND MORE INFORMATION |  | 11

|                      |  | 
|--------------------- |  | 
|                      |  | 
|                      |  | 
|ABOUT THIS PROSPECTUS

This
prospectus incorporates by reference important information. You may obtain the
information incorporated by reference without charge by following the
instructions under Where You Can Find More Information appearing below before
deciding to invest in our shares.

Unless the
context otherwise requires, references in this prospectus to our company,
we, us, our or ours refer to MAKO Surgical Corp.

You should
rely only on the information contained in, and incorporated by reference into,
this prospectus. We have not authorized anyone to provide you with information
different from or in addition to that contained in, or incorporated by
reference into, this prospectus. If anyone provides you with different or
inconsistent information, you should not rely on it. The information contained
in, and incorporated by reference into, this prospectus is accurate only as of
the date of this prospectus, regardless of the time of delivery of this
prospectus or of any sale of the common stock. Our business, financial
conditions, results of operations and prospects may have changed since that
date.

We have
received or applied for trademark registration of and/or claim trademark
rights, including in the following marks that appear in this prospectus:
MAKOplasty®, RIO, RESTORIS®, Tactile Guidance System and TGS,
as well
as in the MAKO Surgical Corp. MAKO logo, whether standing alone or in connection
with the words MAKO Surgical Corp. Any other trademarks, trade names and
service marks appearing in this prospectus or incorporated by reference are the
property of their respective owners.

i

---

CAUTIONARY
STATEMENT ABOUT FORWARD-LOOKING INFORMATION

This
prospectus and any other offering material, and the documents incorporated by
reference in this prospectus and any other offering material, contain
statements that we believe to be forward-looking statements within the
meaning of the U.S. federal securities laws. Statements that are not historical
facts, including statements about our beliefs and expectations, are
forward-looking statements. Forward-looking statements include statements
generally preceded by, followed by or that include the words believe,
could, expect, intend, may, anticipate, plan,
predict,
potential, estimate or similar expressions. These statements include, but
are not limited to, statements related to:

| |   |                                                                                                                                                                                  
| | - | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | the timing
 and number of planned new product introductions;                                                                                                                     
| |   |                                                                                                                                                                                  
| |  | market
 acceptance of the MAKOplasty solution;                                                                                                                                   
| |   |                                                                                                                                                                                  
| |  | the effect
 of anticipated changes in the size, health and activities of population on
 the demand for our products;                                                             
| |   |                                                                                                                                                                                  
| |  | assumptions
 and estimates regarding the size and growth of certain market segments;                                                                                             
| |   |                                                                                                                                                                                  
| |  | our ability
 and intent to expand into international markets;                                                                                                                    
| |   |                                                                                                                                                                                  
| |  | the timing
 and anticipated outcome of clinical studies;                                                                                                                         
| |   |                                                                                                                                                                                  
| |  | assumptions
 concerning anticipated product developments and emerging technologies;                                                                                              
| |   |                                                                                                                                                                                  
| |  | the future
 availability from third-party suppliers, including single source suppliers,
 of components for our robotic arm and implant systems for our knee MAKOplasty
 solution;
| |   |                                                                                                                                                                                  
| |  | the
 viability of maintaining our licensed intellectual property or our ability to
 obtain additional licenses necessary to our growth;                                          
| |   |                                                                                                                                                                                  
| |  | the
 anticipated adequacy of our capital resources to meet the needs of our
 business;                                                                                           
| |   |                                                                                                                                                                                  
| |  | our
 continued investment in new products and technologies;                                                                                                                      
| |   |                                                                                                                                                                                  
| |  | the ultimate
 marketability of newly launched products and products currently being
 developed;                                                                                  
| |   |                                                                                                                                                                                  
| |  | the ability
 to implement new technologies successfully;                                                                                                                         
| |   |                                                                                                                                                                                  
| |  | future
 declarations of cash dividends;                                                                                                                                          
| |   |                                                                                                                                                                                  
| |  | our goals
 for sales and earnings growth;                                                                                                                                        
| |   |                                                                                                                                                                                  
| |  | our ability
 to sustain sales and earnings growth;                                                                                                                               
| |   |                                                                                                                                                                                  
| |  | our success
 in achieving timely approval or clearance of products with domestic and
 foreign regulatory entities;                                                               
| |   |                                                                                                                                                                                  
| |  | the
 stability of certain domestic and foreign economic markets;                                                                                                                 
| |   |                                                                                                                                                                                  
| |  | the impact
 of anticipated changes in the medical device industry and our ability to
 react to and capitalize on those changes;                                                  
| |   |                                                                                                                                                                                  
| |  | our ability
 to take advantage of technological advancements; and                                                                                                                
| |   |                                                                                                                                                                                  
| |  | the impact
 of any managerial changes.                                                                                                                                           

Forward-looking
statements reflect our current expectations and are not guarantees of
performance. These statements are based on managements beliefs and
assumptions, which in turn are based on currently available information.
Important assumptions relating to these forward-looking statements include,
among others, assumptions regarding demand for our products, expected pricing
levels, raw material costs, the timing and cost of planned capital
expenditures, competitive conditions and general economic conditions. You are cautioned
that reliance on any forward-looking statement involves risks and
uncertainties. Although we believe that the assumptions on which the
forward-looking statements contained herein are based are reasonable, any of
those assumptions could prove to be inaccurate given the inherent uncertainties
as to the occurrence or nonoccurrence of

1

---

future events.
There can be no assurance that the forward-looking statements contained in this
prospectus will prove to be accurate. The inclusion of a forward-looking statement
in this report should not be regarded as a representation by us that our
objectives will be achieved.

Forward-looking
statements also involve risks and uncertainties, which could cause actual
results to differ materially from those contained in any forward-looking
statement. Many of these factors are beyond our ability to control or predict
and could, among other things, cause actual results to differ from those
contained in forward-looking statements made in this prospectus. Such factors,
among others, may have a material adverse effect on our business, financial
condition and results of operations and may include, but are not limited to,
factors discussed under Risk Factors below, in Part I, Item 1A, Risk
Factors, of our annual report on Form 10-K for the year ended December 31,
2008, and the following:

| |   |                                                                                                                                                                                                                                                       
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | a further
 economic downturn that may have a significant adverse effect on the ability
 of our customers to secure adequate funding, including access to credit, to
 buy our products or that may cause our customers to delay a purchasing
 decision;
| |   |                                                                                                                                                                                                                                                       
| |  | changes in
 general economic conditions and interest rates;                                                                                                                                                                                           
| |   |                                                                                                                                                                                                                                                       
| |  | changes in
 the availability of capital and financing sources, for our company and our
 customers;                                                                                                                                                    
| |   |                                                                                                                                                                                                                                                       
| |  | changes in
 competitive conditions and prices in our markets;                                                                                                                                                                                         
| |   |                                                                                                                                                                                                                                                       
| |  | changes in
 the relationship between supply of and demand for our products;                                                                                                                                                                           
| |   |                                                                                                                                                                                                                                                       
| |  | fluctuations
 in costs of raw materials and labor;                                                                                                                                                                                                    
| |   |                                                                                                                                                                                                                                                       
| |  | changes in
 other significant operating expenses;                                                                                                                                                                                                     
| |   |                                                                                                                                                                                                                                                       
| |  | unanticipated
 issues related to product launches, particularly the launch of the RIO
 Robotic Arm Interactive Orthopedic system;                                                                                                                     
| |   |                                                                                                                                                                                                                                                       
| |  | decreases in
 sales of our principal product lines;                                                                                                                                                                                                   
| |   |                                                                                                                                                                                                                                                       
| |  | slow downs
 or inefficiencies in our product research and development efforts;                                                                                                                                                                        
| |   |                                                                                                                                                                                                                                                       
| |  | increases in
 expenditures related to increased government regulation of our business;                                                                                                                                                                
| |   |                                                                                                                                                                                                                                                       
| |  | unanticipated
 issues in securing regulatory clearance or approvals for upgrades or changes
 to our products;                                                                                                                                         
| |   |                                                                                                                                                                                                                                                       
| |  | developments
 adversely affecting our potential sales activities outside the United States;                                                                                                                                                           
| |   |                                                                                                                                                                                                                                                       
| |  | increases in
 cost containment efforts by group purchasing organizations;                                                                                                                                                                             
| |   |                                                                                                                                                                                                                                                       
| |  | loss of key
 management and other personnel or inability to attract such management and
 other personnel;                                                                                                                                             
| |   |                                                                                                                                                                                                                                                       
| |  | increases in
 costs of retaining a direct sales force and building a distributor network;                                                                                                                                                             
| |   |                                                                                                                                                                                                                                                       
| |  | unanticipated
 issues related to, or unanticipated changes in or difficulties associated
 with, the recruitment of agents and distributors of our products;                                                                                           
| |   |                                                                                                                                                                                                                                                       
| |  | unanticipated
 expenditures related to any future litigation; and                                                                                                                                                                                     
| |   |                                                                                                                                                                                                                                                       
| |  | unanticipated
 intellectual property expenditures required to develop, market and defend our
 products.                                                                                                                                               

We urge you to
consider these factors before investing in our common stock. We caution you not
to place undue reliance on these forward-looking statements that speak only as
of the date they were made. We do not undertake any obligation to release any
revisions to these forward-looking statements publicly to reflect events or
circumstances after the date of this prospectus or to reflect the occurrence of
unanticipated events.

2

---

PROSPECTUS
SUMMARY

The following summary is qualified in its
entirety by, and should be read together with, the more detailed information
and financial statements and related notes thereto appearing elsewhere in, or
incorporated by reference into, this prospectus. Before you decide to invest in
our common stock, you should read the entire prospectus, including documents
incorporated by reference, carefully, including the risk factors and the
financial statements and related notes.

Overview

We are a
medical device company that markets our advanced robotic arm solution and
orthopedic implants for minimally invasive orthopedic knee procedures. We offer
MAKOplasty, an innovative, restorative surgical solution that enables
orthopedic surgeons to consistently, reproducibly and precisely treat patient
specific, early to mid-stage osteoarthritic knee disease.

MAKOplasty is
performed using our proprietary, U.S. Food and Drug Administration, or
FDA, cleared robotic arm system and proprietary knee resurfacing implants. Our
robotic arm systems, branded as our first generation Tactile Guidance System,
or TGS, and our second generation RIO Robotic Arm Interactive Orthopedic
system, or RIO, utilize tactile guided robotic arm technology and patient
specific visualization to prepare the knee joint for the insertion and
alignment of our resurfacing implants through a small incision in a minimally
invasive, bone preserving and tissue sparing procedure. Our RESTORIS family of
knee implants is designed to enable minimally invasive restoration of one or
two of the diseased compartments of the knee joint. We believe MAKOplasty will
empower physicians to address the needs of the large and growing, yet
underserved population of patients with early to mid-stage osteoarthritic knee
disease who desire a restoration of quality of life and reduction of pain, but
for whom current surgical treatments are not appropriate or desirable due to
the highly invasive nature of such procedures, the slow recovery and the
substantial costs of rehabilitation, medication and hospitalization.

Unlike
conventional knee replacement surgery, which requires extraction and
replacement of the entire joint, MAKOplasty enables resurfacing of one or two
specific diseased compartments of the joint, preserving significantly more soft
tissue and healthy bone of the knee. We believe localized resurfacing can be
optimized using our robotic arm technology, which offers consistently
reproducible precision to surgeons to achieve optimal implant placement and
alignment for smaller, more easily inserted modular implant components. We
believe that the tissue sparing and bone conserving techniques enabled with
MAKOplasty can offer substantial advantages to patients, surgeons and
healthcare providers. Because of the minimally invasive nature of the
procedure, smaller incisions are possible, which lead to less tissue loss and
faster recoveries, thereby reducing the overall costs of rehabilitation,
medication and hospitalization. In addition, because more of the patients
natural anatomy is preserved and less trauma is inflicted on the knee, we
believe that patients who undergo MAKOplasty have the potential to experience
better functionality and more natural knee movements, thereby achieving an
improved post-operative quality of life. Significantly, the expansion of our
RESTORIS family of implants for use in single and bicompartmental knee
resurfacing procedures provides the ability to address a broader range of the
patient population suffering from early to mid-stage osteoarthritis. Finally,
because our robotic arm systems are easy to use, we believe that our MAKOplasty
solution makes resurfacing procedures accessible to orthopedic surgeons with a
broad range of training and skills and has the potential to lead to greater
adoption of knee resurfacing solutions for early to mid-stage osteoarthritis of
the knee.

In May 2005,
we obtained 510(k) marketing clearance from the FDA for a haptic imageless
surgical guidance system. In November 2005, we obtained 510(k) marketing
clearance from the FDA for version 1.0 of our TGS, a CT based patient specific
visualization system with a robotic arm, which was the predecessor device to
our RIO system and enabled MAKOplasty for a single compartment of the knee
joint using a standard unicompartmental implant. In January 2008, we received
510(k) marketing clearance from the FDA for version 1.2 of our TGS, which
allowed for MAKOplasty using an alternative standard unicompartmental knee
implant and incorporated several software upgrades developed and introduced
since the commercial introduction of version 1.0. We commercially launched
version 1.2 in the first quarter of 2008 and version 1.3 (the modifications to
which did not require 510(k) marketing clearance) in the third quarter of 2008.
In the first quarter of 2006 we received 510(k) clearance for our tibial inlay
knee implant system and in the fourth quarter of 2007 we received 501(k)
clearance for our tibial onlay knee implant system and for our combined inlay
and onlay system, branded as RESTORIS. In the second quarter of 2008, we

3

---

received
510(k) clearance for our unicompartmental knee implant and 510(k) clearance for
our patellofemoral knee implant, predecessor components of our proprietary
multicompartmental implant system. In the fourth quarter of 2008, we received
510(k) marketing clearance from the FDA for the RIO system, which is version
2.0 of our TGS, and our multicompartmental knee implant system, branded as
RESTORIS MCK. We intend to commercially launch both the RIO system and the
RESTORIS MCK multicompartmental knee implant system in the first half of 2009.

As part of the
TGS sales contracts, TGS customers are entitled to receive an upgrade of their
TGS unit to a RIO system at no additional charge, with the exception of one
customer who had the right to receive it at a discounted price. Through
December 31, 2008, we commercially installed seventeen TGS units, all of which
achieved customer acceptance, and installed one additional non-commercial unit
for research and evaluation purposes. As of December 31, 2008, 782 knee
MAKOplasty procedures had been performed since commercial introduction in June
2006. We currently have 22 post-market studies of MAKOplasty, either recently
completed or in progress, which are aimed at demonstrating the accuracy of the
placement and alignment of our knee implants and the clinical value of the
MAKOplasty procedure. To date, the results of these studies have been presented
internationally as peer-reviewed presentations at conferences in the United
States and abroad. We have an intellectual property portfolio of more than 250
licensed or owned patents and patent applications relating to the areas of
computer assisted surgery, robotics, haptics and implants.

We generate
revenue from unit sales of our TGS, sales of our implants and disposable
products and the sale of extended warranty service contracts. We anticipate
generating revenue from future sales of RIO systems. To date, we have
recognized revenue primarily from the sale of implants and disposable products
utilized in MAKOplasty procedures. Recognition of deferred revenue in our
statements of operations associated with the sale of TGS units depends on delivery
of the RIO system, which we intend to commercially launch in the first half of
2009.

Corporate Information

We were
incorporated in Delaware in November 2004 under the name MAKO Surgical Corp.
The address of our principal executive office is 2555 Davie Road, Fort
Lauderdale, Florida 33317, and our telephone number is (954) 927-2044. Our
website address is www.makosurgical.com. We do not incorporate the information
on our website into this prospectus, and you should not consider it part of
this prospectus. In February 2008, our common stock began trading on The NASDAQ
Global Market under the ticker symbol MAKO and we closed our initial public
offering, or IPO.

4

---

RISK FACTORS

An investment in our common stock involves a
high degree of risk. You should carefully consider the following risks and the
risks set forth in Part I, Item 1A, Risk Factors, of our annual report on
Form 10-K for the year ended December 31, 2008, as well as all of the other
information contained in, or incorporated by reference into, this prospectus,
before investing in our common stock. If any of the following possible events
actually occur, our business, business prospects, cash flow, results of
operations or financial condition could be harmed. In this case, the trading
price of our common stock could decline, and you might lose all or part of your
investment in our common stock. In assessing these risks, you should also refer
to the other information contained in, or incorporated by reference into, this
prospectus, including our financial statements and related notes. Additional
risks and uncertainties not presently known to us or that we currently deem
immaterial may also impair our operations. Some
factors in this section are forward-looking statements. For a discussion
of those statements, see Cautionary Statement About Forward-Looking
Information.

Risks Related to
Investing in and Ownership of our Common Stock

We expect that the
price of our common stock will fluctuate substantially, which could lead to
losses for stockholders, possibly resulting in class action securities
litigation.

Prior to our
IPO in February 2008, there was no public market for shares of our common
stock. Since the IPO, our common stock has experienced significant price
fluctuations and low trading volumes. An active public trading market may not
develop or, if developed, may not be sustained. The market price for our common
stock will be affected by a number of factors, including:

| |   |                                                                                                                                                                          
| | - | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | the receipt,
 denial or timing of regulatory clearances or approvals of our products or
 competing products;                                                             
| |   |                                                                                                                                                                          
| |  | changes in
 policies affecting third-party coverage and reimbursement in the U.S. and
 other countries;                                                                  
| |   |                                                                                                                                                                          
| |  | ability of
 our products, if they receive regulatory clearance, to achieve market
 success;                                                                              
| |   |                                                                                                                                                                          
| |  | the
 performance of third-party contract manufacturers and component suppliers;                                                                                          
| |   |                                                                                                                                                                          
| |  | our ability
 to develop sales and marketing capabilities;                                                                                                                
| |   |                                                                                                                                                                          
| |  | our ability
 to manufacture our products to commercial standards;                                                                                                        
| |   |                                                                                                                                                                          
| |  | the success
 of any collaborations we may undertake with other companies;                                                                                                
| |   |                                                                                                                                                                          
| |  | our ability
 to develop, introduce and market new or enhanced versions of our products on
 a timely basis;                                                               
| |   |                                                                                                                                                                          
| |  | actual or
 anticipated variations in our results of operations or those of our competitors;                                                                              
| |   |                                                                                                                                                                          
| |  | announcements
 of new products, technological innovations or product advancements by us or
 our competitors;                                                             
| |   |                                                                                                                                                                          
| |  | developments
 with respect to patents and other intellectual property rights;                                                                                            
| |   |                                                                                                                                                                          
| |  | sales of
 common stock or other securities by us or our stockholders in the future;                                                                                      
| |   |                                                                                                                                                                          
| |  | additions or
 departures of key scientific or management personnel;                                                                                                      
| |   |                                                                                                                                                                          
| |  | disputes or
 other developments relating to proprietary rights, including patents,
 litigation matters and our ability to obtain patent protection for our
 technologies;

5

---

| |   |                                                                                                                                                                                         
| | - | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | trading
 volume of our common stock;                                                                                                                                                    
| |   |                                                                                                                                                                                         
| |  | changes in
 earnings estimates or recommendations by securities analysts, failure to
 obtain analyst coverage of our common stock or our failure to achieve analyst
 earnings estimates;
| |   |                                                                                                                                                                                         
| |  | developments
 in our industry; and                                                                                                                                                      
| |   |                                                                                                                                                                                         
| |  | general
 market conditions and other factors unrelated to our operating performance or
 the operating performance of our competitors.                                                   

In addition,
the stock prices of many companies in the medical device industry have
experienced wide fluctuations that have often been unrelated to the operating
performance of these companies. We expect our stock price to be similarly
volatile. These broad market fluctuations may continue and could harm our stock
price. Following periods of volatility in the market price of a companys
securities, stockholders have often instituted class action securities
litigation against those companies. Class action securities litigation, if
instituted against us, could result in substantial costs and a diversion of our
management resources, which could significantly harm our business.

Securities analysts
may issue negative reports or cease to cover our common stock, which may have a
negative impact on the market price of our common stock.

The trading
market for our common stock may be affected in part by the research and reports
that industry or financial analysts publish about us or our business. As a
result of our smaller market capitalization, it may be difficult for our
company to continue to attract securities analysts that will cover our common
stock. If one or more of the analysts who elects to cover us downgrades our
stock, our stock price would likely decline rapidly. If one or more of these
analysts ceases coverage of our company, we could lose visibility in the
market, which in turn could cause our stock price to decline. This could have a
negative effect on the market price of our stock.

Our principal
stockholders, directors and executive officers own a large percentage of our
voting stock, which allows them to exercise significant influence over matters
subject to stockholder approval.

As of March 2,
2009, our executive officers, directors and principal stockholders holding 5%
or more of our outstanding common stock beneficially owned or controlled
approximately 60.1% of the outstanding shares of our common stock. Accordingly,
these executive officers, directors and principal stockholders, acting as a
group, have substantial influence over the outcome of corporate actions
requiring stockholder approval, including the election of directors, any
merger, consolidation or sale of all or substantially all of our assets or any
other significant corporate transaction. These stockholders may also delay or
prevent a change of control or otherwise discourage a potential acquirer from
attempting to obtain control of us, even if such a change of control would
benefit our other stockholders. This significant concentration of stock
ownership may adversely affect the trading price of our common stock due to
investors perception that conflicts of interest may exist or arise.

We have not paid
dividends in the past and do not expect to pay dividends in the foreseeable
future.

We have never
declared or paid cash dividends on our capital stock. We currently intend to
retain all future earnings for the operation and expansion of our business and,
therefore, do not anticipate declaring or paying cash dividends in the
foreseeable future. The payment of dividends will be at the discretion of our
board of directors and will depend on our results of operations, capital
requirements, financial condition, prospects, contractual arrangements, any
limitations on payments of dividends present in any of our future debt
agreements, and other factors our board of directors may deem relevant. If we
do not pay dividends, a return on your investment will only occur if our stock
price appreciates.

Sales of a
substantial number of shares of our common stock in the public market, or the
perception that they may occur, may depress the market price of our common
stock.

We cannot
predict the effect, if any, that market sales of shares of our common stock or
the availability of such shares upon the effectiveness of a registration
statement, or upon the expiration of any holding period under Rule 144, will
have on the market price prevailing from time to time. The effectiveness of our
registration statement on Form S-1, declared effective by the SEC on December
9, 2008, under which we registered for resale approximately 13.0 million shares
of our common stock sold in the October 2008 private placement described below, issued upon
conversion of our previously outstanding convertible preferred stock, or that
may be acquired upon exercise of warrants sold in the

6

---

equity
financing, and the expiration of the holding periods under Rule 144, create a
circumstance commonly referred to as an overhang that could depress the
market price of our common stock. The existence of an overhang, whether or not
sales have occurred or are occurring, also could make more difficult our
ability to raise additional financing through the sale of equity or
equity-related securities in the future at a time and price that we deem
reasonable or appropriate.

Approximately all of the 25.0 million shares of our common stock currently outstanding are freely tradable without registration
pursuant to Rule 144 under the Securities Act or have been registered for
resale with the U.S. Securities and Exchange Commission, or SEC, and the sale
of such shares could have a negative impact on the price of our common stock.

Our recent capital
raising transaction, and our need to raise additional capital in the future,
could have a negative effect on your investment.

We may need to
raise additional capital in the future in order for us to continue to operate
our business. In October 2008, we raised approximately $40.2 million in gross
proceeds through the sale in a private placement of our common stock and
warrants to purchase shares of our common stock. Under the terms of the private
placement, we granted the investors in the private placement additional
warrants to purchase 322,581 shares of our common stock at an exercise price of
$6.20 per share in exchange for a right to require, under certain
circumstances, the investors to purchase an additional $20,000,000 in shares of
our common stock and warrants to purchase shares of our common stock. We may,
in the future, also raise additional capital through the public or private sale
of common stock or securities convertible into or exercisable for our common
stock. Such sales could be consummated at a significant discount to the trading
price of our stock.

If we sell
additional shares of our common stock, such sales will further dilute the percentage
of our equity that our existing stockholders own. In addition, private
placement financings could involve the issuance of securities at a price per
share that represents a discount to the trading prices of our common stock.
Further, debt and equity financings may involve the issuance of dilutive
warrants. No assurance can be given that previous or future investors, finders
or placement agents will not claim that they are entitled to additional
anti-dilution adjustments or dispute the calculation of any such adjustments.
Any such claim or dispute could require us to incur material costs and expenses
regardless of the resolution and, if resolved unfavorably to us, to effect
dilutive securities issuances or adjustment to previously issued securities.

The private
placement in October 2008 included, and future financings may include,
provisions requiring us to make additional payments to the investors if we fail
to obtain or maintain the effectiveness of SEC registration statements by
specified dates or take other specified action. Our ability to meet these
requirements may depend on actions by regulators and other third parties, over
which we will have no control. These provisions may require us to make payments
or could lead to costly and disruptive disputes. In addition, these provisions
could require us to record additional non-cash expenses. Such provisions in
future financings could also require us to issue additional dilutive
securities, although the provisions of the private placement in October 2008 include
no such requirement.

We are obligated to
develop and maintain proper and effective internal control over financial
reporting, and we may not complete our analysis of our internal control over
financial reporting in a timely manner or this internal control may not be
determined to be effective, which may adversely affect investor confidence in
our company and, as a result, the value of our common stock.

We are
required, pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section
404, to furnish a report by management on, among other things, the
effectiveness of our internal control over financial reporting beginning in
this annual report on Form 10-K. This assessment concluded that no material
weaknesses in our internal control over financial reporting have been
identified by our management as of December 31, 2008. If our auditors are
unable to express an opinion on the effectiveness of our internal control over
financial reporting, which, in accordance with SEC rules will be required as of
December 31, 2009, we could lose investor confidence in the accuracy and
completeness of our financial reports, which would have a material adverse
effect on the price of our common stock. Future failure to comply with the
rules might make it more difficult for us to obtain certain types of insurance,
including director and officer liability insurance, and we might be forced to
accept reduced policy limits and coverage and/or incur substantially higher
costs to obtain the same or similar coverage. The impact of these events could
also make it more difficult for us to attract and retain qualified persons to
serve on our board of directors, on committees of our board of directors, or as
executive officers.

7

---

In addition,
as a public company, we incur significant additional legal, accounting and
other expenses that we did not incur as a private company, and our
administrative staff is required to perform additional tasks. For example, we
have increased the size of our accounting staff, updated our accounting systems
and procedures, revised the roles and duties of our board committees, retained
a transfer agent, adopted an insider trading policy and disclosure controls and
procedures and are bearing all of the internal and external costs of preparing
and distributing periodic public reports in compliance with our obligations
under the securities laws. Changing laws, regulations and standards relating to
corporate governance and public disclosure, and related regulations implemented
by the SEC and The NASDAQ Global Market, are creating uncertainty for public
companies, increasing legal and financial compliance costs and making some
activities more time consuming. These laws, regulations and standards are
subject to varying interpretations, in many cases due to their lack of
specificity, and, as a result, their application in practice may evolve over
time as new guidance is provided by regulatory and governing bodies. We are
investing resources to comply with evolving laws, regulations and standards,
and this investment will result in increased general and administrative
expenses and a diversion of managements time and attention from revenue
generating activities to compliance activities. If our efforts to comply with
new laws, regulations and standards differ from the activities intended by
regulatory or governing bodies due to ambiguities related to practice,
regulatory authorities may initiate legal proceedings against us and our
business may be harmed.

8

---

USE OF
PROCEEDS

This
prospectus relates to shares of our common stock that may be offered and sold
from time to time by the selling stockholder named in this prospectus or a
prospectus supplement. All proceeds from the sale of the shares covered by this
prospectus will be for the account of the selling stockholder. See Selling
Stockholder and Plan of Distribution below.

We will not
receive any of the proceeds from the sale of the common stock. We have agreed
to bear all expenses (other than direct expenses incurred by the selling
stockholder, such as selling commissions, brokerage fees and expenses and
transfer taxes) associated with registering such shares under federal and state
securities laws.

SELLING
STOCKHOLDER

On behalf of
the selling stockholder named in the table below (including his donees,
pledgees, transferees or other successors-in-interest who receive any of the
shares covered by this prospectus), we are registering, pursuant to the
registration statement of which this prospectus is a part, 741,075 shares of
our common stock, all of which are issued and outstanding. The shares were
awarded to the selling stockholder under our 2004 Stock Incentive Plan. Our
registration of the shares does not necessarily mean that the selling
stockholder will sell all or any of the shares.

We are
registering the shares to permit the selling stockholder to offer these shares
for resale from time to time. The selling stockholder may sell all, some or
none of the shares covered by this prospectus. All information with respect to
beneficial ownership has been furnished to us by the selling stockholder. For
more information, see the section of this prospectus entitled Plan Of
Distribution.

The table
below lists the selling stockholder and information regarding his ownership of
common stock as of March 2, 2009:

|                             |  |                                                         |         |                                           |  |                                                    |  |        |         |               |  |   | 
|---------------------------- |  | ------------------------------------------------------- | ------- | ----------------------------------------- |  | -------------------------------------------------- |  | ------ | ------- | ------------- |  | - | 
|Name of
 Selling Stockholder |  | Number of Shares
 Beneficially Owned
 Prior to Offering |         | Number of Shares
 Registered for
 Sale(1) |  | Shares Owned
 After Sale of
 Registered
 Shares(1) | 
|                             |  |                                                         |         |                                           |  |                                                    |  | Number |         | Percentage(2) | 
|Maurice R.
 Ferré, M.D.(3)   |  |                                                         | 875,995 |                                           |  | 741,075                                            |  |        | 134,920 |               |  | * | 

* Less than
1%.

(1) Assumes
that the stockholder disposes of all the shares of common stock covered by this
prospectus and does not acquire or dispose of any additional shares of common
stock. The selling stockholder is not representing, however, that any of the
shares covered by this prospectus will be offered for sale, and the selling
stockholder reserves the right to accept or reject, in whole or in part, any
proposed sale of shares.

(2) The
percentage of common stock beneficially owned is based on 24,984,927 shares of
common stock outstanding on March 2, 2009 and assumes the exercise of any
warrants and options owned by the selling stockholder, but not the exercise of
any other outstanding options or warrants.

(3) Dr. Ferré is our founding President, Chief
Executive Officer and current Chairman
of our board of directors. The number of shares listed under Number of Shares
Beneficially Owned Prior to Offering consists of 741,075 shares of
restricted common stock (of which 234,690 shares were unvested as of March
2, 2009) issued to Dr. Ferré in connection with his employment,
17,065 shares of unrestricted common stock purchased by Dr. Ferré,
49,504 shares of restricted common stock held by MMF Holdings, LLC, an entity
owned by Dr. Ferrés parents, 62,720 shares that Dr. Ferré has the right to
acquire through the exercise of vested options and 5,631 shares that
Dr. Ferré has the right to acquire through the exercise of warrants. Of
his 506,385 vested shares of restricted common stock, Dr. Ferré has pledged
125,000 shares to a third party lender as collateral to secure any amounts that
may become outstanding under a personal loan.

9

---

PLAN OF DISTRIBUTION

We are
registering the shares covered by this prospectus that were previously issued
to the selling stockholder to permit the resale of these shares by the selling
stockholder from time to time after the date of this prospectus. We will
not receive any of the proceeds from the sale of the shares by the selling
stockholder. We will bear all fees and expenses incident to our obligation
to register the shares.

The selling
stockholder may use any one or more of the following methods when selling
shares:

| |   |                                                                                                                                                                                   
| | - | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | ordinary
 brokerage transactions and transactions in which the broker-dealer solicits
 purchasers;                                                                                
| |   |                                                                                                                                                                                   
| |  | block trades
 in which the broker-dealer will attempt to sell the shares as agent but may
 position and resell a portion of the block as principal to facilitate the
 transaction;
| |   |                                                                                                                                                                                   
| |  | purchases by
 a broker-dealer as principal and resale by the broker-dealer for its account;                                                                                       
| |   |                                                                                                                                                                                   
| |  | an exchange
 distribution in accordance with the rules of the applicable exchange;                                                                                                
| |   |                                                                                                                                                                                   
| |  | privately
 negotiated transactions;                                                                                                                                               
| |   |                                                                                                                                                                                   
| |  | short sales;                                                                                                                                                                      
| |   |                                                                                                                                                                                   
| |  | broker-dealers
 may agree with the selling stockholder to sell a specified number of such
 shares at a stipulated price per share;                                                
| |   |                                                                                                                                                                                   
| |  | a
 combination of any such methods of sale; and                                                                                                                                   
| |   |                                                                                                                                                                                   
| |  | any other
 method permitted pursuant to applicable law.                                                                                                                           

Further, the
selling stockholder may choose to dispose of the shares by gift to a third
party or as a donation to a charitable or other non-profit entity. In
connection with any sales, the selling stockholder and any brokers
participating in such sales may be deemed to be underwriters within the meaning
of the Securities Act of 1933, as amended (the Securities Act).

Any
broker-dealer participating in such transactions as agent may receive
commissions from the selling stockholder (and, if such broker acts as agent for
the purchaser of such shares, from such purchaser). The selling
stockholder will pay usual and customary brokerage fees. A broker-dealer
may agree with the selling stockholder to sell a specified number of shares at
a stipulated price per share, and, to the extent such a broker-dealer is unable
to do so acting as agent for the selling stockholder, to purchase as principal
any unsold shares at the price required to fulfill the broker-dealer commitment
to the selling stockholder. A broker-dealer who acquires shares as principal
may thereafter resell such shares from time to time in transactions (which may
involve crosses and block transactions and which may involve sales to and
through other broker-dealers, including transactions of the nature described
above) in the over-the-counter market, in negotiated transactions or otherwise
at market prices prevailing at the time of sale or at negotiated prices, and in
connection with such resales may pay to or receive from the purchasers of such
shares commissions computed as described above.

Under
applicable rules and regulations under the Securities Exchange Act of
1934, as amended (the Exchange Act), any person engaged in the distribution
of the resale shares may not simultaneously engage in market making activities
with respect to the shares for the applicable restricted period, as defined in
Regulation M, prior to the commencement of the distribution. In addition,
the selling stockholder will be subject to applicable provisions of the
Exchange Act and the rules and regulations thereunder, including Regulation M,
which may limit the timing of purchases and sales of the shares by the
selling stockholder or any other person.

Any
commissions paid or any discounts or concessions allowed to any such
broker-dealer, and, if any such broker-dealer purchases shares as principal,
any profits received on the resale of such shares, may be deemed to be
underwriting discounts and commissions under the Securities Act.

If applicable,
upon our being notified by the selling stockholder that any material
arrangement has been entered into with a broker-dealer for the sale of the
shares through a cross or block trade, a supplemental prospectus will be filed
under Rule 424(c) under the Securities Act, setting forth the name of
the participating broker-dealer(s), the number of the shares involved, the
price at which the selling stockholder sold such shares, the commissions paid
or discounts or concessions allowed by the selling stockholder to such
broker-dealer(s), and, where applicable, that such broker-dealer(s) did
not conduct any investigation to verify the information set out in this
prospectus. Any securities

10

---

covered by
this prospectus that qualify for sale pursuant to Rule 144 under the
Securities Act may be sold under that Rule rather than pursuant to this
prospectus. There can be no assurance that the selling stockholder will
sell any or all of the shares offered under this prospectus.

LEGAL
MATTERS

Foley &
Lardner LLP will pass upon the validity of the common stock being offered by
this prospectus.

EXPERTS

The financial
statements of MAKO Surgical Corp. appearing in MAKO Surgical Corp.s Annual
Report (Form 10-K) for the year ended December 31, 2008, have been audited by
Ernst & Young LLP, independent registered public accounting firm, as set
forth in their report thereon, included therein, and incorporated herein by
reference. Such financial statements are incorporated herein by reference in
reliance upon such report given on the authority of such firm as experts in
accounting and auditing.

WHERE YOU CAN
FIND MORE INFORMATION

We file
annual, quarterly and current reports, proxy statements and other information
with the SEC. We have also filed a registration statement on Form S-8 under the
Securities Act with respect to the shares of common stock offered by this prospectus.
This prospectus is a part of the Form S-8, but does not contain all of the
information included in the Form S-8 or the exhibits. Some items are omitted in
accordance with the rules and regulations of the SEC. You may read and copy the
registration statement and any other document that we file at the SECs public
reference room at 100 F Street, N.E., Washington DC, 20549. You can call the
SEC at 1-800-SEC-0330 for further information on the operation of the public
reference room. You can also find our public filings with the SEC on the
internet at a web site maintained by the SEC located at http://www.sec.gov.

We are
incorporating by reference specified documents that we file with the SEC,
which means:

|                                                         |   |                                                                                                                                                                                                      
|-------------------------------------------------------- | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|                                                         |  | incorporated
 documents are considered part of this prospectus; and                                                                                                                                  
|                                                         |   |                                                                                                                                                                                                      
|                                                         |  | we are
 disclosing important information to you by referring you to those documents.                                                                                                                 
|                                                         |   |                                                                                                                                                                                                      
|We
 incorporate by reference the documents listed below:
|                                                        
|                                                         |  | our Annual
 Report on Form 10-K for the year ended December 31, 2008;                                                                                                                                
|                                                         |   |                                                                                                                                                                                                      
|                                                         |  | our Current
 Reports on Form 8-K filed February 13, 2009, February 20, 2009 and March 10, 2009; and                                                                                                  
|                                                         |   |                                                                                                                                                                                                      
|                                                         |  | the
 description of our common stock contained in our Registration Statement on
 Form 8-A filed February 14, 2008, and any amendments or reports filed for the
 purpose of updating such description.

All documents
we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the
Securities Exchange Act of 1934 after the date of this registration statement
on Form S-8, of which this prospectus is a part, and prior to the termination
of this offering, shall be deemed to be incorporated by reference into this
prospectus and to be part of this prospectus from the date of the filing of the
documents with the SEC.

11

---

We will
provide to each person to whom a prospectus is delivered a copy of any of the
filings incorporated by reference into this prospectus, at no cost, upon
written or oral request directed to us at the following address or telephone
number:

| |                                   
| | ----------------------------------
| | Investor
 Relations               
| | MAKO
 Surgical Corp.              
| | 2555 Davie
 Road                  
| | Fort
 Lauderdale, FL 33317        
| | (954)
 927-2044                   
| | investorrelations@makosurgical.com

You can also
find these filings on our website at www.makosurgical.com. However, we are not
incorporating the information on our website other than these filings into this
prospectus.

12

---

PART
II

INFORMATION REQUIRED IN THE REGISTRATION
STATEMENT

|        |                                        
|------- | ---------------------------------------
|Item 3. | Incorporation of Documents by Reference

The
following documents filed with the SEC by MAKO Surgical Corp. (the Company)
are incorporated herein by reference:

| |   |                                                                                                                                                                                                      
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | Our Annual
 Report on Form 10-K for the year ended December 31, 2008;                                                                                                                                
| |   |                                                                                                                                                                                                      
| |  | Our Current
 Reports on Form 8-K filed February 13, 2009, February 20, 2009 and March 10, 2009; and                                                                                                  
| |   |                                                                                                                                                                                                      
| |  | The
 description of our common stock contained in our Registration Statement on
 Form 8-A filed February 14, 2008, and any amendments or reports filed for the
 purpose of updating such description.

All
documents subsequently filed by the Company pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act, prior to the filing of a post-effective
amendment which indicates that all securities offered hereby have been sold or
which deregisters all securities then remaining unsold shall be deemed to be
incorporated by reference into this registration statement on Form S-8 and to
be a part hereof from the date of filing of such documents. Any statement
contained herein or in a document, all or a portion of which is incorporated or
deemed to be incorporated by reference herein, shall be deemed to be modified or
superseded for purposes of this Registration Statement to the extent that a
statement contained herein or in any other subsequently filed document which
also is or is deemed to be incorporated by reference herein modifies or
supersedes such statement. Any such statement so modified or superseded shall
not be deemed, except as so modified or amended, to constitute a part of this
Registration Statement.

|        |                          
|------- | -------------------------
|Item 4. | Description of Securities

Not
applicable.

|        |                                       
|------- | --------------------------------------
|Item 5. | Interests of Named Experts and Counsel

Not
applicable.

|        |                                          
|------- | -----------------------------------------
|Item 6. | Indemnification of Directors and Officers

The
Company is incorporated under the laws of the State of Delaware.
Section 145 of the Delaware General Corporation Law provides that a
Delaware corporation may indemnify any persons who are, or are threatened to be
made, parties to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative or investigative (other
than an action by or in the right of such corporation), by reason of the fact
that such person was an officer, director, employee or agent of such
corporation, or is or was serving at the request of such person as an officer,
director, employee or agent of another corporation or enterprise. The indemnity
may include expenses (including attorneys fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by such person in
connection with such action, suit or proceeding, provided that such person
acted in good faith and in a manner he or she reasonably believed to be in or
not opposed to the corporations best interests and, with respect to any
criminal action or proceeding, had no reasonable cause to believe that his or
her conduct was illegal. A Delaware corporation may indemnify any persons who
are, or are threatened to be made, a party to any threatened, pending or
completed action or suit by or in the right of the corporation by reason of the
fact that such person was a director, officer, employee or agent of such
corporation, or is or was serving at the request of such corporation as a
director, officer, employee or agent of another corporation or enterprise. The
indemnity may include expenses (including attorneys fees) actually and
reasonably incurred by such person in connection with the defense or settlement
of such action or suit provided such person acted in good faith and in a manner
he or she reasonably believed to be in or not opposed to the corporations best
interests except that no indemnification is permitted without judicial approval
if the officer or director is adjudged to be liable to the corporation.
Expenses incurred by any officer or director in defending any such action, suit
or proceeding in advance of its final disposition shall be paid by the Company
upon delivery to the Company of an undertaking, by or on behalf of such
director or

II-1

---

officer, to repay all amounts so
advanced if it shall ultimately be determined that such director or officer is
not entitled to be indemnified by the Company. Where an officer or director is
successful on the merits or otherwise in the defense of any action referred to
above, the corporation must indemnify him or her against the expenses which
such officer or director has actually and reasonably incurred. The Companys third
amended and restated certificate of incorporation and third amended and
restated bylaws provide for the indemnification of the Companys directors and
officers to the fullest extent permitted under the Delaware General Corporation
Law.

Section 102(b)(7)
of the Delaware General Corporation Law permits a corporation to provide in its
certificate of incorporation that a director of the corporation shall not be
personally liable to the corporation or its stockholders for monetary damages for
breach of fiduciary duties as a director, except for liability for any:

| |   |                                                                                                          
| | - | ---------------------------------------------------------------------------------------------------------
| |  | transaction from which the
 director derives an improper personal benefit,                               
| |   |                                                                                                          
| |  | act or omission not in good
 faith or that involves intentional misconduct or a knowing violation of law,
| |   |                                                                                                          
| |  | unlawful payment of dividends
 or redemption of shares, or                                               
| |   |                                                                                                          
| |  | breach of a directors duty of
 loyalty to the corporation or its stockholders.                          

The Companys third amended and
restated certificate of incorporation includes such a provision.

Section 174
of the Delaware General Corporation Law provides, among other things, that a
director, who willfully or negligently approves of an unlawful payment of
dividends or an unlawful stock purchase or redemption, may be held liable for
such actions. A director who was either absent when the unlawful actions were
approved, or dissented at the time, may avoid liability by causing his or her
dissent to such actions to be entered in the books containing minutes of the
meetings of the board of directors at the time such action occurred or
immediately after such absent director receives notice of the unlawful acts.

As
permitted by the Delaware General Corporation Law, the Company has entered into
indemnity agreements with each of its directors and executive officers, that
require the Company to indemnify such persons against any and all expenses
(including attorneys fees), witness fees, damages, judgments, fines,
settlements and other amounts incurred (including expenses of a derivative
action) in connection with any action, suit or proceeding, whether actual or
threatened, to which any such person may be made a party by reason of the fact
that such person is or was a director, an officer or an employee of the Company
or any of its affiliated enterprises, provided that such person acted in good
faith and in a manner such person reasonably believed to be in or not opposed
to the Companys best interests and, with respect to any criminal proceeding,
had no reasonable cause to believe his or her conduct was unlawful. The
indemnification agreements also set forth certain procedures that will apply in
the event of a claim for indemnification thereunder.

At
present, there is no pending litigation or proceeding involving any of the
Companys directors or executive officers as to which indemnification is
required or permitted, and the Company is not aware of any threatened
litigation or proceeding that may result in a claim for indemnification.

The
Company has an insurance policy covering its officers and directors with
respect to certain liabilities, including liabilities arising under the
Securities Act or otherwise.

|        |                                     
|------- | ------------------------------------
|Item 7. | Exemption from Registration Claimed.

The shares being registered by
this Registration Statement on Form S-8 were issued in reliance on the
exemption from registration provided by Section 4(2) of the Securities Act or
regulations promulgated thereunder. Such shares were issued to the selling
stockholder pursuant to the MAKO Surgical Corp. 2004 Stock Incentive Plan.

|        |          
|------- | ---------
|Item 8. | Exhibits.

The exhibits
filed herewith or incorporated herein by reference are set forth in the
attached Exhibit Index.

II-2

---

|        |              
|------- | -------------
|Item 9. | Undertakings.

(a)          The
undersigned Registrant hereby undertakes:

(1)          To
file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration Statement:

| |                                                                                                                                                                                                                                                                                                                             
| | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | (i)          To
 include any prospectus required by Section 10(a)(3) of the Securities Act of
 1933;                                                                                                                                                                                                                        
| |                                                                                                                                                                                                                                                                                                                             
| | (ii)          To
 reflect in the prospectus any facts or events arising after the effective
 date of the Registration Statement (or the most recent post-effective
 amendment thereof) which, individually or in the aggregate, represent a
 fundamental change in the information set forth in the Registration
 Statement;
| |                                                                                                                                                                                                                                                                                                                             
| | (iii)          To
 include any material information with respect to the plan of distribution not
 previously disclosed in the Registration Statement or any material change to
 such information in the Registration Statement;                                                                                             

provided, however,
that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information
required to be included in a post-effective amendment by those paragraphs is
contained in reports filed with or furnished to the Securities and Exchange
Commission by the Registrant pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934 that are incorporated by reference in
the Registration Statement.

(2)          That,
for the purpose of determining any liability under the Securities Act of 1933,
each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered herein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering
thereof.

(3)          To
remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the
offering.

(b)          The
undersigned Registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act of 1933, each filing of the Registrants
annual report pursuant to Section 13(a) or Section 15(d) of the Securities
Exchange Act of 1934 that is incorporated by reference in this Registration
Statement shall be deemed to be a new registration statement relating to the
securities offered herein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.

(c)          Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may
be permitted to directors, officers and controlling persons of the Registrant
pursuant to the foregoing provisions, or otherwise, the Registrant has been
advised that in the opinion of the Commission such indemnification is against
public policy as expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the
payment by the Registrant of expenses incurred or paid by a director, officer
or controlling person of the Registrant in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the Registrant
will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as
expressed in the Act and will be governed by the final adjudication of such
issue.

II-3

---

SIGNATURES

Pursuant to
the requirements of the Securities Act of 1933, the Registrant certifies that
it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-8 and has duly caused this Registration Statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Fort Lauderdale, State of Florida, on this 12th day of March,
2009.

| |                     |                                           | 
| | ------------------- | ----------------------------------------- | 
| | MAKO Surgical Corp. |                                          
| |                     |                                          
| | By:                 | /s/ Maurice
 R. Ferré                     | 
| |                     |                                           | 
| |                     | Maurice R.
 Ferré, M.D.                   | 
| |                     | President and Chief Executive Officer and
| |                     | Chairman of the Board                    

POWER
OF ATTORNEY

Each person
whose signature appears below constitutes and appoints Maurice R. Ferré and
Fritz L. LaPorte, and each of them individually, his true and lawful
attorney-in-fact and agent, with full powers of substitution and
resubstitution, for him and in his name, place and stead, in any and all
capacities, to sign any and all amendments (including post-effective amendments)
to this Registration Statement, and to file the same, with all exhibits
thereto, and other documents in connection therewith, with the SEC, granting
unto said attorneys-in-fact and agents, and each of them individually, full
power and authority to do and perform each and every act and thing requisite
and necessary to be done in and about the premises, as fully to all intents and
purposes as he or she might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents, or any of them
individually, or their substitute or substitutes, may lawfully do or cause to
be done by virtue hereof.

Pursuant to
the requirements of the Securities Act, this Registration Statement has been
signed below by the following persons in the capacities and on the dates
indicated.

|                                |  |                                                         |  |                
|------------------------------- |  | ------------------------------------------------------- |  | ---------------
|Signature                       |  | Title                                                   |  | Date           
|                                |  |                                                         |  |                
|/s/ Maurice
 R. Ferré, M.D.     |  | President,
 Chief Executive Officer and Chairman of the |  |                
|Maurice R.
 Ferré, M.D.         |  | Board
 (Principal Executive Officer)                    |  | March 12,
 2009
|                                |  |                                                         |  |                
|/s/ Fritz L. LaPorte            |  | Senior Vice
 President of Finance and Administration,   |  |                
|Fritz L. LaPorte                |  | Chief
 Financial Officer and Treasurer                  |  | March 12, 2009 
|                                |  | (Principal
 Accounting and Financial Officer)           |  |                
|                                |  |                                                         |  |                
|/s/ S. Morry
 Blumenfeld, Ph.D. |  | Director                                                |  | March 12, 2009 
|S. Morry
 Blumenfeld, Ph.D.     |  |                                                         |  |                
|                                |  |                                                         |  |                
|/s/ Gerald A.
 Brunk            |  | Director                                                |  | March 12, 2009 
|Gerald A.
 Brunk                |  |                                                         |  |                
|                                |  |                                                         |  |                
|/s/ Marcelo G. Chao             |  | Director                                                |  | March 12, 2009 
|Marcelo G. Chao                 |  |                                                         |  |                
|                                |  |                                                         |  |                
|/s/ Christopher
 C. Dewey       |  | Director                                                |  | March 12, 2009 
|Christopher
 C. Dewey           |  |                                                         |  |                

S-1

---

|                            |  |          |  |               
|--------------------------- |  | -------- |  | --------------
|/s/ Charles
 W. Federico    |  | Director |  | March 12, 2009
|Charles W.
 Federico        |  |          |  |               
|                            |  |          |  |               
|/s/ John G.
 Freund, M.D.   |  | Director |  | March 12, 2009
|John G.
 Freund, M.D.       |  |          |  |               
|                            |  |          |  |               
|/s/ Frederic
 H. Moll, M.D. |  | Director |  | March 12, 2009
|Frederic H.
 Moll, M.D.     |  |          |  |               
|                            |  |          |  |               
|/s/ William
 D. Pruitt      |  | Director |  | March 12, 2009
|William D.
 Pruitt          |  |          |  |               
|                            |  |          |  |               
|/s/ John J.
 Savarese, M.D. |  | Director |  | March 12, 2009
|John J.
 Savarese, M.D.     |  |          |  |               

S-2

---

EXHIBIT
INDEX

|               |  |                                                                                   |                      | 
|-------------- |  | --------------------------------------------------------------------------------- | -------------------- | 
|Exhibit Number |  |                                                                                   | Document Description | 
|               |  |                                                                                   |                      | 
|4              |  | MAKO
 Surgical Corp. 2004 Stock Incentive Plan (1)                               
|               |  |                                                                                  
|5              |  | Opinion of
 Foley & Lardner LLP (including consent of counsel) (2)               
|               |  |                                                                                  
|23.1           |  | Consent of
 Foley & Lardner LLP (filed as part of Exhibit (5)) (2).              
|               |  |                                                                                  
|23.2           |  | Consent of
 Ernst & Young LLP, Independent Registered Public Accounting Firm (2).
|               |  |                                                                                  
|24             |  | Powers of
 Attorney (2).                                                         

Documents
incorporated by reference to filings made by MAKO Surgical Corp. under the
Securities Exchange Act of 1934, as amended, are under Securities and Exchange
Commission (SEC) File No. 001-33966.

|    |                                                                                                                                                                          | 
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | 
|    |                                                                                                                                                                         
|   
|(1) | Incorporated
 by reference to the Registrants Registration Statement on Form S-1, as
 amended, filed with the SEC on September 19, 2007 (Registration No.
 333-146162).
|    |                                                                                                                                                                         
|(2) | Filed
 herewith.                                                                                                                                                        

E-1

---